FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.16), $0.16 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $50.6 million versus the consensus estimate of $34.66 million.

GUIDANCE:

FibroGen sees FY2024 revenue of $135-150 million, versus the consensus of $153.5 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.